A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled (Open-Label), Phase IIa Clinical Study to Evaluate the Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 11 Mar 2026
At a glance
- Drugs DBM 1152A (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Joincare Pharmaceutical
Most Recent Events
- 11 Mar 2026 New trial record